We serve Chemical Name:2-bromoquinoline-4-carbonitrile CAS:95104-24-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-bromoquinoline-4-carbonitrile
CAS.NO:95104-24-8
Synonyms:2-bromo-4-cyanoquinoline
Molecular Formula:C10H5BrN2
Molecular Weight:233.06400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:279.2ºC at 760mmHg
Density:1.66g/cm3
Index of Refraction:1.702
PSA:36.68000
Exact Mass:231.96400
LogP:2.86898
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-bromo-4-cyanoquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-4-cyanoquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-bromo-4-cyanoquinoline Use and application,2-bromo-4-cyanoquinoline technical grade,usp/ep/jp grade.
Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-bromoquinoline-4-carbonitrile manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-bromoquinoline-4-carbonitrile supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 2-bromoquinoline-4-carbonitrile vendor The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 2-bromoquinoline-4-carbonitrile factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.
